{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T11:53:53Z","timestamp":1781610833309,"version":"3.54.5"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:00:00Z","timestamp":1750982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:00:00Z","timestamp":1750982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medizinische Hochschule Hannover (MHH)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Extramedullary disease in patients with newly diagnosed multiple myeloma is rare and, despite the abundance of new therapeutic options, is still associated with a dismal prognosis, classifying as an unmet clinical need. Here, we report the case of a young woman diagnosed with multiple myeloma and extensive extramedullary disease characterised by diffuse lymph node involvement. The patient received multiple chemotherapy regimens proving to be refractory to all of them and ultimately benefited from salvage therapy with Venetoclax combination therapy, with a complete disappearance of the extramedullary manifestations. This case proves the effectiveness of Venetoclax in t(11;14) myeloma with extramedullary involvement.<\/jats:p>","DOI":"10.1007\/s00277-025-06489-6","type":"journal-article","created":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T04:31:42Z","timestamp":1750998702000},"page":"4223-4227","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness of venetoclax based therapy in t(11;14) multiple myeloma with extensive extramedullary disease: a case report"],"prefix":"10.1007","volume":"104","author":[{"given":"Kerstin","family":"Brinkert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Heinrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Brioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Heuser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans Heinrich","family":"Kreipe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian H.","family":"Heidel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold","family":"Ganser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gernot","family":"Beutel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,27]]},"reference":[{"issue":"12","key":"6489_CR1","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV et al (2014) International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15(12):538\u2013548. https:\/\/doi.org\/10.1016\/S1470-2045(14)70442-5","journal-title":"Lancet Oncol"},{"issue":"3","key":"6489_CR2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41408-022-00643-3","volume":"12","author":"J Blad\u00e9","year":"2022","unstructured":"Blad\u00e9 J, Beksac M, Caers J, Jurczyszyn A, von Lilienfeld-Toal M, Moreau P et al (2022) Extramedullary disease in multiple myeloma: a systematic literature review. Blood Cancer J 12(3):45. https:\/\/doi.org\/10.1038\/s41408-022-00643-3","journal-title":"Blood Cancer J"},{"issue":"10","key":"6489_CR3","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1002\/ajh.27023","volume":"98","author":"S Zanwar","year":"2023","unstructured":"Zanwar S, Ho M, Lin Y, Kapoor P, Binder M, Buadi FK et al (2023) Natural history, predictors of development of extramedullary disease, and treatment outcomes for patients with extramedullary multiple myeloma. Am J Hematol. 98(10):1540\u20131549. https:\/\/doi.org\/10.1002\/ajh.27023 Erratum in: Am J Hematol. 2024;99(10):2055. https:\/\/doi.org\/10.1002\/ajh.27403","journal-title":"Am J Hematol."},{"issue":"32","key":"6489_CR4","doi-asserted-by":"publisher","first-page":"3602","DOI":"10.1200\/JCO.21.00443","volume":"10","author":"NJ Bahlis","year":"2021","unstructured":"Bahlis NJ, Baz R, Harrison SJ, Quach H, Ho SJ, Vangsted AJ et al (2021) Phase I study of venetoclax plus daratumumab and dexamethasone, with or without bortezomib, in patients with relapsed or refractory multiple myeloma with and without t(11;14). J Clin Oncol 10(32):3602\u20133612. https:\/\/doi.org\/10.1200\/JCO.21.00443","journal-title":"J Clin Oncol"},{"issue":"3","key":"6489_CR5","doi-asserted-by":"publisher","first-page":"182","DOI":"10.3390\/curroncol32030182","volume":"20","author":"M Ho","year":"2025","unstructured":"Ho M, Paruzzo L, Minehart J, Nabar N, Noll JH, Luo T et al (2025) Extramedullary multiple myeloma: challenges and opportunities. Curr Oncol 20(3):182. https:\/\/doi.org\/10.3390\/curroncol32030182","journal-title":"Curr Oncol"},{"issue":"12","key":"6489_CR6","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/S1470-2045(20)30525-8","volume":"21","author":"SK Kumar","year":"2020","unstructured":"Kumar SK, Harrison SJ, Cavo M, de la Rubia J, Popat R, Gasparetto C et al (2020) Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol 21(12):1630\u20131642","journal-title":"Lancet Oncol"},{"issue":"19","key":"6489_CR7","doi-asserted-by":"publisher","first-page":"3748","DOI":"10.1182\/bloodadvances.2020004146","volume":"5","author":"LJ Costa","year":"2021","unstructured":"Costa LJ, Davies FE, Monohan GP, Kovacsovics T, Burwick N, Jakubowiak A et al (2021) Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed\/refractory multiple myeloma. Blood Adv 5(19):3748\u20133759. https:\/\/doi.org\/10.1182\/bloodadvances.2020004146","journal-title":"Blood Adv"},{"issue":"22","key":"6489_CR8","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1182\/blood-2017-06-788786","volume":"30","author":"S Kumar","year":"2017","unstructured":"Kumar S, Kaufman JL, Gasparetto C, Mikhael J, Vij R, Pegourie B et al (2017) Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11;14) multiple myeloma. Blood 30(22):2401\u20132409. https:\/\/doi.org\/10.1182\/blood-2017-06-788786","journal-title":"Blood"},{"issue":"22","key":"6489_CR9","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1182\/blood-2017-06-788323","volume":"30","author":"P Moreau","year":"2017","unstructured":"Moreau P, Chanan-Khan A, Roberts AW, Agarwal AB, Facon T, Kumar S et al (2017) Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed\/refractory MM. Blood 30(22):2392\u20132400. https:\/\/doi.org\/10.1182\/blood-2017-06-788323","journal-title":"Blood"},{"issue":"1","key":"6489_CR10","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1186\/s12885-023-11553-3","volume":"3","author":"X Gao","year":"2023","unstructured":"Gao X, Zeng H, Zhao X, Wu H, Yan M, Li Y et al (2023) Efficacy and safety of venetoclax in patients with relapsed\/refractory multiple myeloma: a meta-analysis. BMC Cancer 3(1):1058\u20131053. https:\/\/doi.org\/10.1186\/s12885-023-11553-3","journal-title":"BMC Cancer"},{"issue":"4","key":"6489_CR11","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/ajh.26083","volume":"96","author":"JL Kaufman","year":"2021","unstructured":"Kaufman JL, Gasparetto C, Schjesvold FH, Moreau P, Touzeau C, Facon T et al (2021) Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed\/refractory t(11;14) multiple myeloma. Am J Hematol 96(4):418\u2013427. https:\/\/doi.org\/10.1002\/ajh.26083","journal-title":"Am J Hematol"},{"key":"6489_CR12","doi-asserted-by":"publisher","first-page":"7510","DOI":"10.1200\/JCO.2024.42.16_suppl.7510","volume":"42","author":"NJ Bahlis","year":"2024","unstructured":"Bahlis NJ, Popat R, Beksac M, Dimopoulos MA, Gatt ME, Gay F et al (2024) Efficacy of venetoclax-dexamethasone (VenDex) v pomalidomide-dexamethasone (PomDex) in patients (Pts) with t(11;14)-positive relapsed\/refractory multiple myeloma [t(11;14)\u2009+\u2009RRMM]: phase 3 CANOVA study biomarker subgroup analysis. JCO 42:7510\u20137510. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.7510","journal-title":"JCO"},{"issue":"12","key":"6489_CR13","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.6004\/jnccn.2023.0061","volume":"21","author":"SK Kumar","year":"2023","unstructured":"Kumar SK, Callander NS, Adekola K, Anderson LDJ, Baljevic M, Baz R et al (2023) Multiple myeloma, version 2.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 21(12):1281\u20131301. https:\/\/doi.org\/10.6004\/jnccn.2023.0061","journal-title":"J Natl Compr Canc Netw"},{"issue":"14","key":"6489_CR14","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1182\/blood.2022017789","volume":"141","author":"N Giesen","year":"2023","unstructured":"Giesen N, Chatterjee M, Scheid C, Poos AM, Besemer B, Miah K et al (2023) A phase 2 clinical trial of combined BRAF\/MEK Inhibition for BRAFV600E-mutated multiple myeloma. Blood 141(14):1685\u20131690. https:\/\/doi.org\/10.1182\/blood.2022017789","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06489-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06489-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06489-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T11:17:06Z","timestamp":1781608626000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06489-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,27]]},"references-count":14,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["6489"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06489-6","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,27]]},"assertion":[{"value":"20 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from the patient for their anonymized information to be published in this case report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent"}},{"value":"AB: has participated in advisory boards from BMS, Janssen, GSK, Pfizer, AstraZeneca and Sanofi and received honoraria and travel support from BMS, Janssen, GSK, Sanofi, Amgen and AstraZeneca. The remaining authors have no relevant financial or non-financial interests to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}